(Q30580112)

25 June 2017

1 reference

title

From enhancing lesions to brain atrophy in relapsing MS. (English)

1 reference

25 June 2017

Simon JH

1

1 reference

25 June 2017

publication date

1 July 1999

1 reference

Journal of Neuroimmunology

25 June 2017

published in

1 reference

25 June 2017

volume

98

1 reference

25 June 2017

issue

1

1 reference

25 June 2017

page(s)

7-15

1 reference

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Corpus callosum in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

The longstanding MS lesion. A quantitative MRI and electron microscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Chemical pathology of acute demyelinating lesions and its correlation with disability

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Multiple sclerosis and corpus callosum atrophy: relationship of MRI findings to clinical data.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Stereotactic biopsy of an active multiple sclerosis lesion. Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

A spinal cord MRI study of benign and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Magnetic resonance imaging correlates of dementia in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Cerebral disconnection in multiple sclerosis. Relationship to atrophy of the corpus callosum

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900075-2

7 January 2021

10.1016/S0165-5728(99)00075-2

Identifiers

DOI

1 reference

25 June 2017

1 reference